Yoshiike, Takuya
Utsumi, Tomohiro
Matsui, Kentaro
Nagao, Kentaro
Saitoh, Kaori
Otsuki, Rei
Aritake-Okada, Sayaka
Suzuki, Masahiro
Kuriyama, Kenichi
Funding for this research was provided by:
Ministry of Health, Labor and Welfare, Government of Japan (#19FA1009)
Article History
Received: 1 October 2021
Accepted: 14 December 2021
First Online: 7 January 2022
Competing interests
: Dr. Yoshiike reports personal fees from MSD and Takeda Pharmaceutical outside the submitted work. Dr. Utsumi reports personal fees from Eisai outside the submitted work. Dr. Matsui reports personal fees from Eisai, Meiji Seika Pharma, Mochida, MSD, Otsuka Pharmaceutical, and Yoshitomi Pharmaceutical outside the submitted work. Dr. Saitoh reports personal fees from Yoshitomi Pharmaceutical outside the submitted work. Dr. Aritake-Okada reports grants from Kao Corporation, grants and personal fees from Takeda Pharmaceutical, and personal fees from Idorsia Pharma and MSD outside the submitted work. Dr. Suzuki reports grants from Novartis and Shionogi Pharmaceutical, grants and personal fees from Dainippon Sumitomo, Eisai, Mochida Pharmaceutical, Otsuka Pharmaceutical, and Takeda Pharmaceutical, and personal fees from EA Pharma, Meiji Seika Pharma, MSD, and Pfizer outside the submitted work. Dr. Kuriyama reports grants from Otsuka Pharmaceutical, Mitsubishi Tanabe Pharma, Shionogi Pharma, Pfizer, Kao Corporation, and PMC Corporation, grants and personal fees from Meiji Seika Pharma, Eisai, MSD, Takeda Pharmaceutical, Tsumura, and Eli Lilly, and personal fees from Yoshitomi Pharmaceutical outside the submitted work. No other disclosures were reported.